We found that S/R tumors had increased PD-L1 expression (relatively to non-S/R RCC) independent of CD274 copy number status (any deletion, amplification, or neither; all deletions were one-copy deletions); although the three S/R patients with CD274 gene amplification (1 patient with high amplification and 2 with low amplifications) all expressed PD-L1 by IHC above the cut-off of ≥1%. Here, CD274 is linked to renal cell carcinoma.